PLX 8-K 2026-11-10

Protalix BioTherapeutics, Inc. (PLX) 8-K dated 2026-11-10 — accession 0001104659-26-124761.

Protalix BioTherapeutics, Inc. (PLX) is a biotechnology company listed on US.

PLX: Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Busin…

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported PLX revenue for 2025-12-31 was $52.7M. Net income was -$6.6M. Revenue was down 1.2% from 2024-12-31 to 2025-12-31. PLX currently screens at market cap $122.6M.

Not investment advice. The PLX SEC hub lists recent forms. The stock page is the research view.